The Oncogenomics Handbook

Product Description

An integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following a systems biology approach, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including Ritux an, Erbitux, Gleevec Herceptin, Avastin, ABX-EGF, Velcade, Kepivance, Iressa, Tarceva, and Zevalin are addressed. Highlights include cancer genomics, pharmacogenomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation.
Product Details

* Amazon Sales Rank: #2410378 in Books
* Published on: 2005-04-15
* Original language: English
* Number of items: 1
* Binding: Hardcover
* 768 pages

Editorial Reviews

Review
"...an excellent resource to anyone interested in the field of cancer or cancer research. Its comprehensive overview of different perspectives in oncologic genomics will certainly be beneficial to a wide range of professionals in their ultimate endeavors towards further development of advanced cancer therapies." - Doody's Health Sciences and Book Review Journal

"...provides an integrated overview of cancer drug discovery and development...." - BioTech International
Customer Reviews

Thorough Review of Genomics-Based Cancer Research5
This work draws on the experience of dozens of leading scientists in the public and private sector in their efforts to use information from genomics to understand and develop cancer therapies. A wide variety of experimental cancer drugs are discussed, and clinical trial data are presented. At 750 pages it is a substantial work, with enough technical detail to suit the bench scientist and physician, yet an easy enough read to be appreciated by the avid learner.